Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance

Infinity avoids the erosion of its rights to a promising PI3K drug by restructuring its alliance with Purdue and Mundipharma, essentially returning all control back to the cancer drug developer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet